Comparison of 60 or 90 mg/m2 of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. Issue 2 (19th November 2014) - Devillier, Raynier; Bertoli, Sarah; Prébet, Thomas; Huguet, Françoise; Etienne, Anne; Charbonnier, Aude; Rey, Jérôme; Delabesse, Eric; D'Incan, Evelyne; Huynh, Anne; Blaise, Didier; Récher, Christian; et al.